Katelyn Parker-McGill1, Melodee Nugent1,2, Rachel Bersie1, Gary Hoffman3, Michael Rock4, Mei Baker3,4, Philip M Farrell4, Pippa Simpson1,2, Hara Levy1,5. 1. Children's Research Institute, Children's Hospital of Wisconsin, Milwaukee, Wisconsin. 2. Quantitative Health Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin. 3. Wisconsin State Lab of Hygiene, Madison, Wisconsin. 4. Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. 5. Division of Pulmonary and Sleep Medicine, Children's Hospital of Wisconsin, Milwaukee, Wisconsin.
Abstract
RATIONALE: Previous investigations of cystic fibrosis (CF) incidence in Massachusetts, Colorado, and Minnesota (USA) yielded contradictory results, particularly regarding allele p.Phe508del; the racial compositions of the cohorts were not reported. OBJECTIVES: To clarify discrepancies in reported incidence with the ultimate goal of improving screening and quality of care, we assessed CF incidence, stratified by race and mutations in cystic fibrosis transmembrane conductance regulator (CFTR), in Wisconsin (USA) from 1994 to 2011. METHODS: Data on patients diagnosed with CF (N = 283), CFTR genotypes, CF carriers, and birth rate were collected. All data were categorized by racial background of the birth mother and the incidence of CF births was accordingly adjusted. Spearman's nonparametric rank correlation and Fisher's exact test were performed for continuous and categorical variables, respectively. Trends over time were fitted with a cubic spline. RESULTS: We detected a trending increase in CF cases (range within all data 1.67-2.98 per 10,000 births per year), homozygous p.Phe508del cases (0.57-1.79 per 10,000), heterozygous p.Phe508del cases (0.29-1.55 per 10,000), and cases lacking p.Phe508del (0-0.45 per 10,000). Both the number of cases lacking the p.Phe508del mutation per year and the number of cases lacking p.Phe508del per 10,000 births significantly increased (P = 0.05) from 1994 to 2011; the increase in overall incidence was not significant. The number of carriers identified through newborn screening significantly increased within the non-Hispanic Black (P = 0.0.021) and Hispanic (P = 0.003) populations. CONCLUSION: The racial composition of the CF cohort is changing in Wisconsin, possibly influencing disease detection, care, and outcome.
RATIONALE: Previous investigations of cystic fibrosis (CF) incidence in Massachusetts, Colorado, and Minnesota (USA) yielded contradictory results, particularly regarding allele p.Phe508del; the racial compositions of the cohorts were not reported. OBJECTIVES: To clarify discrepancies in reported incidence with the ultimate goal of improving screening and quality of care, we assessed CF incidence, stratified by race and mutations in cystic fibrosis transmembrane conductance regulator (CFTR), in Wisconsin (USA) from 1994 to 2011. METHODS: Data on patients diagnosed with CF (N = 283), CFTR genotypes, CF carriers, and birth rate were collected. All data were categorized by racial background of the birth mother and the incidence of CF births was accordingly adjusted. Spearman's nonparametric rank correlation and Fisher's exact test were performed for continuous and categorical variables, respectively. Trends over time were fitted with a cubic spline. RESULTS: We detected a trending increase in CF cases (range within all data 1.67-2.98 per 10,000 births per year), homozygous p.Phe508del cases (0.57-1.79 per 10,000), heterozygous p.Phe508del cases (0.29-1.55 per 10,000), and cases lacking p.Phe508del (0-0.45 per 10,000). Both the number of cases lacking the p.Phe508del mutation per year and the number of cases lacking p.Phe508del per 10,000 births significantly increased (P = 0.05) from 1994 to 2011; the increase in overall incidence was not significant. The number of carriers identified through newborn screening significantly increased within the non-Hispanic Black (P = 0.0.021) and Hispanic (P = 0.003) populations. CONCLUSION: The racial composition of the CF cohort is changing in Wisconsin, possibly influencing disease detection, care, and outcome.
Authors: Philip M Farrell; HuiChuan J Lai; Zhanhai Li; Michael R Kosorok; Anita Laxova; Christopher G Green; Jannette Collins; Gary Hoffman; Ronald Laessig; Michael J Rock; Mark L Splaingard Journal: J Pediatr Date: 2005-09 Impact factor: 4.406
Authors: Mitchell L Drumm; Michael W Konstan; Mark D Schluchter; Allison Handler; Rhonda Pace; Fei Zou; Maimoona Zariwala; David Fargo; Airong Xu; John M Dunn; Rebecca J Darrah; Ruslan Dorfman; Andrew J Sandford; Mary Corey; Julian Zielenski; Peter Durie; Katrina Goddard; James R Yankaskas; Fred A Wright; Michael R Knowles Journal: N Engl J Med Date: 2005-10-06 Impact factor: 91.245
Authors: S Carles; M Desgeorges; A Goldman; R Thiart; C Guittard; C A Kitazos; T J de Ravel; A T Westwood; M Claustres; M Ramsay Journal: J Med Genet Date: 1996-09 Impact factor: 6.318
Authors: P M Farrell; M R Kosorok; A Laxova; G Shen; R E Koscik; W T Bruns; M Splaingard; E H Mischler Journal: N Engl J Med Date: 1997-10-02 Impact factor: 91.245
Authors: E H Mischler; B S Wilfond; N Fost; A Laxova; C Reiser; C M Sauer; L M Makholm; G Shen; L Feenan; C McCarthy; P M Farrell Journal: Pediatrics Date: 1998-07 Impact factor: 7.124
Authors: Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen Journal: Lancet Respir Med Date: 2019-09-27 Impact factor: 30.700